Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Generic Health

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods in Australia, ensuring that these goods are of acceptable quality, efficacy, and safety. The Act was introduced to address the need for a comprehensive regulatory system that governs the importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood and blood components. Enacted by the Parliament of Australia, the Act aims to protect public health by controlling the quality and safety of therapeutic goods available in the market. The Therapeutic Goods Administration (TGA), an agency within the Department of Health, administers the Act to enforce compliance and safeguard consumer interests. The policy objective of the Act is to ensure that therapeutic goods are safe, of acceptable quality, and their benefits outweigh any risks, while also facilitating access to therapeutic goods that meet these standards. On 27 October 2015, under sections 14 and 14A of the Therapeutic Goods Act 1989, a delegate of the Secretary of the Department of Health granted consent to Generic Health for the supply of specific batches of Pharmacy Action Low Dose Aspirin. This consent was issued to address non-compliance with certain labelling requirements as stipulated in the Therapeutic Goods Order No 69, which mandates specific warnings and sponsor information on medicine labels. The consent, which applies solely to the specified batches and is effective until 30 June 2016, includes conditions to rectify the labelling deficiencies, ensuring that the required warning statements and the updated sponsor address are included on the product labels.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods, including medicines, medical devices, blood and blood components, tissues, and vaccines, within Australia. This legislation is enforced by the Therapeutic Goods Administration (TGA), an agency of the Department of Health, and its jurisdictional reach is national. The Act regulates the importation, supply, manufacture, and advertising of therapeutic goods, ensuring they meet safety, quality, and efficacy standards. The Act applies to individuals, entities, and industries involved in any aspect of the lifecycle of therapeutic goods. Notably, the Act provides for exemptions and exclusions, such as for research purposes or for goods intended for personal use, as specified in the legislation or subordinate instruments. The application of the Act can be extended or restricted through regulations and orders, including those that pertain to specific categories of goods or particular circumstances of supply. In the specific case referenced, Generic Health was granted consent under sections 14 and 14A of the Therapeutic Goods Act 1989 for the supply of certain batches of Pharmacy Action Low Dose Aspirin that do not conform to labelling requirements due to missing warning statements and an outdated sponsor address. This consent is limited to the specified batches and is effective until 30 June 2016, subject to conditions that ensure consumer safety and information accuracy. This example illustrates how the Act and its associated regulations can provide flexibility to address particular issues while maintaining the overarching goal of protecting public health.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) allow a delegate of the Secretary of the Department of Health to consent to the supply of therapeutic goods under specific conditions if they do not comply with certain requirements. In this case, the delegate has consented to the supply of specific batches of Pharmacy Action Low Dose Aspirin, AUST R 190572, with batch numbers 350293A and 350293B. These batches do not meet the labelling requirements outlined in paragraphs 3(2)(g) and (l) of Therapeutic Goods Order No 69, as they lack the new warning statements specified in Schedule 2 to the Medicines Advisory Statements Specification 2014 and the new address of the sponsor. The consent is in effect from the date of the notice until 30 June 2016, exclusively for these batches. The Act imposes several obligations on the parties involved in this consent. Firstly, the supplier, Generic Health, must ensure that the labels of the affected batches include the specific warning statement detailed in Schedule 1 of the Medicines Advisory Statements Specification 2014. Additionally, the company is required to set up a redirection service with Australia Post to ensure that any correspondence sent to the previous address (Level 1, 1175 Toorak Rd) is forwarded to the new address (Level 1, 1102 Toorak Rd) until the expiry date of these batches. This measure ensures that all communications are appropriately directed and that the updated information is disseminated effectively. Failure to comply with the conditions of this consent can result in various legal consequences. Under the Therapeutic Goods Act 1989, supplying non-compliant therapeutic goods can lead to civil or criminal penalties. The specific penalties for breaches can include fines and, in severe cases, imprisonment. The exact penalties depend on the nature and severity of the breach, as outlined in the Act and any related regulations. It is crucial for Generic Health to adhere to the conditions to avoid any legal repercussions and to ensure the safety and efficacy of the therapeutic goods supplied.